Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmaceutical Product Development, Inc. (NASDAQ:
) (referred to as "PPD" or the “Company”) to affiliates of The Carlyle Group ("Carlyle") and Hellman & Friedman LP (“Hellman & Friedman”) in a cash transaction valued at approximately $3.9 billion.
Under the terms of the agreement, Carlyle and Hellman & Friedman will acquire all of the outstanding common shares of PPD for $33.25 per share in cash. The transaction is currently expected to close in the fourth quarter of 2011.
Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders.
If you are a holder of PPD common stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.
If you are a shareholder of PPD and would like more information about our investigation, please contactJoshua M. Lifshitz, Esq. by telephone at (866) 313-6222 or by sending an e-mail including your contact information to:
. All e-mail correspondence should make reference to PPD.
Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at
. © 2011 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41
Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter